Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

Product portfolio
Potentially strong market reviews
Competitive analytics
Prospect partners
Mergers and acquisitions project data
Latest trends across a particular industry area
Research and development strategies
The analysis of new customers
A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853

Sort by:

Copper Transporting ATPase 2 (Copper Pump 2 or Wilson Disease Associated Protein or ATP7B or EC 7.2.2.8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Copper Transporting ATPase 2 (Copper Pump 2 or Wilson Disease Associated Protein or ATP7B or EC 7.2.2.8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 36 pages

Corneal Graft Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Corneal Graft Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Corneal Graft Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 37 pages

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Coronary Artery Disease (CAD) (Ischemic Heart Disease) Dr...

May 2022 91 pages

Corrosive Esophagitis (Erosive Esophagitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Corrosive Esophagitis (Erosive Esophagitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Corrosive Esophagitis (Erosive Esophagitis) Drugs in Development by...

May 2022 36 pages

Corticobasal Degeneration (CBD-CBGD-Cortical Basal Ganglionic Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Corticobasal Degeneration (CBD-CBGD-Cortical Basal Ganglionic Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Corticobasal Degeneration (CBD/CBGD/...

May 2022 36 pages

Corticotropin Releasing Factor Receptor 1 (Corticotropin Releasing Hormone Receptor 1 or CRHR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Corticotropin Releasing Factor Receptor 1 (Corticotropin Releasing Hormone Receptor 1 or CRHR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players S...

May 2022 37 pages

CREB Binding Protein (CREBBP or EC 2.3.1.48) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CREB Binding Protein (CREBBP or EC 2.3.1.48) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY CREB Binding Protein (CREBBP or EC 2.3.1.48)...

May 2022 44 pages

Creutzfeldt Jakob Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Creutzfeldt Jakob Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Creutzfeldt Jakob Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 38 pages

Crimean-Congo Hemorrhagic Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Crimean-Congo Hemorrhagic Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Crimean-Congo Hemorrhagic Fever Drugs in Development by Stages, Target, MoA, RoA...

May 2022 38 pages

Cruzipain (Major Cysteine Proteinase or Cruzain or EC 3.4.22.51) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cruzipain (Major Cysteine Proteinase or Cruzain or EC 3.4.22.51) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cruzipain (Major Cystein...

May 2022 35 pages

Cryptococcal Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cryptococcal Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cryptococcal Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 39 pages

Cushings Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cushings Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cushing's Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Pla...

May 2022 42 pages

Cutaneous Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cutaneous Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cutaneous Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Mo...

May 2022 47 pages

Cutaneous T-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cutaneous T-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cutaneous T-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 125 pages

Cyclic GMP-AMP Synthase (23-cGAMP Synthase or Mab 21 Domain Containing Protein 1 or CGAS or EC 2.7.7.86) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cyclic GMP-AMP Synthase (23-cGAMP Synthase or Mab 21 Domain Containing Protein 1 or CGAS or EC 2.7.7.86) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 38 pages

Cyclin Dependent Kinase (CDK or EC 2.7.11.22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cyclin Dependent Kinase (CDK or EC 2.7.11.22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cyclin Dependent Kinase (CDK or EC 2.7.11.2...

May 2022 184 pages

Cyclin Dependent Like Kinase 5 (Serine-Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cyclin Dependent Like Kinase 5 (Serine-Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) Drugs in Development by The...

May 2022 36 pages

Cystine-Glutamate Transporter (Amino Acid Transport System Xc or Calcium Channel Blocker Resistance Protein CCBR1 or Solute Carrier Family 7 Member 11 or xCT or SLC7A11) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cystine-Glutamate Transporter (Amino Acid Transport System Xc or Calcium Channel Blocker Resistance Protein CCBR1 or Solute Carrier Family 7 Member 11 or xCT or SLC7A11) Drugs in Development by Therap...

May 2022 36 pages

Cystinuria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cystinuria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cystinuria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides a...

May 2022 38 pages

Cytokine Receptor Common Subunit Gamma (Interleukin 2 Receptor Subunit Gamma or GammaC or p64 or CD132 or IL2RG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cytokine Receptor Common Subunit Gamma (Interleukin 2 Receptor Subunit Gamma or GammaC or p64 or CD132 or IL2RG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 51 pages

Cytokine Release Syndrome (Cytokine Storm) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cytokine Release Syndrome (Cytokine Storm) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cytokine Release Syndrome (Cytokine Storm) Drugs in Development by St...

May 2022 48 pages

Cytopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cytopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cytopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an...

May 2022 116 pages

Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SU...

May 2022 41 pages

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players...

May 2022 113 pages

D Amino Acid Oxidase (DAAO or DAMOX or DAO or EC 1.4.3.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D Amino Acid Oxidase (DAAO or DAMOX or DAO or EC 1.4.3.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D Amino Acid Oxidase (DAAO or D...

May 2022 35 pages

D1A Dopamine Receptor (Dopamine D1 Receptor or DRD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D1A Dopamine Receptor (Dopamine D1 Receptor or DRD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D1A Dopamine Receptor (Dopamine D1 R...

May 2022 66 pages

D1B Dopamine Receptor (D5 Dopamine Receptor or D1 Beta Dopamine Receptor or Dopamine D5 Receptor or DRD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D1B Dopamine Receptor (D5 Dopamine Receptor or D1 Beta Dopamine Receptor or Dopamine D5 Receptor or DRD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 45 pages

D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D2 Dopamine Receptor (Dopamine D2 Rec...

May 2022 140 pages

D3 Dopamine Receptor (Dopamine D3 Receptor or DRD3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D3 Dopamine Receptor (Dopamine D3 Receptor or DRD3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D3 Dopamine Receptor (Dopamine D3 Rec...

May 2022 83 pages

D4 Dopamine Receptor (D2C Dopamine Receptor or Dopamine D4 Receptor or DRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D4 Dopamine Receptor (D2C Dopamine Receptor or Dopamine D4 Receptor or DRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D4 Dopamine...

May 2022 51 pages

Dedifferentiated Liposarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dedifferentiated Liposarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dedifferentiated Liposarcoma Drugs in Development by Stages, Target, MoA, RoA, Mole...

May 2022 51 pages

Delayed Graft Function (DGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Delayed Graft Function (DGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Delayed Graft Function (DGF) Drugs in Development by Stages, Target, MoA, RoA, Mole...

May 2022 39 pages

Delta Type Opioid Receptor (DOR1 or OPRD or OPRD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Delta Type Opioid Receptor (DOR1 or OPRD or OPRD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Delta Type Opioid Receptor (DOR1 or OP...

May 2022 87 pages

Dementia Associated With Alzheimers Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dementia Associated With Alzheimers Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dementia Associated With Alzheimer's Disease Drugs in Development by...

May 2022 67 pages

Dental Caries Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dental Caries Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dental Caries Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players prov...

May 2022 35 pages

Dental Pain (Toothache-Tooth Pain) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dental Pain (Toothache-Tooth Pain) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dental Pain (Toothache/Tooth Pain) Drugs in Development by Stages, Target, Mo...

May 2022 38 pages

Dermatological Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dermatological Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dermatological Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...

May 2022 61 pages

Diabetic Neuropathic Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Diabetic Neuropathic Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Diabetic Neuropathic Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 75 pages

Diastolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Diastolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Diastolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 61 pages

Dihydrofolate Reductase (DHFR or EC 1.5.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Dihydrofolate Reductase (DHFR or EC 1.5.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Dihydrofolate Reductase (DHFR or EC 1.5.1.3)...

May 2022 47 pages

Dihydroorotate Dehydrogenase (Quinone) Mitochondrial (Dihydroorotate Oxidase or DHODH or EC 1.3.5.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Dihydroorotate Dehydrogenase (Quinone) Mitochondrial (Dihydroorotate Oxidase or DHODH or EC 1.3.5.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Play...

May 2022 50 pages

DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D...

May 2022 40 pages

DNA Directed RNA Polymerase (POLR2 or EC 2.7.7.6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Directed RNA Polymerase (POLR2 or EC 2.7.7.6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Directed RNA Polymerase (POLR2 or E...

May 2022 69 pages

DNA Repair Protein RAD51 Homolog 1 (RAD51 Homolog A or RAD51) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Repair Protein RAD51 Homolog 1 (RAD51 Homolog A or RAD51) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Repair Protein RAD51 Ho...

May 2022 37 pages

DNA Topoisomerase I (TOP1 or EC 5.99.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Topoisomerase I (TOP1 or EC 5.99.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Topoisomerase I (TOP1 or EC 5.99.1.2) Drugs...

May 2022 97 pages

DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Topoisomerase II (EC 5.99.1.3) Drugs in Developmen...

May 2022 110 pages

DNA Topoisomerase IV (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Topoisomerase IV (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Topoisomerase IV (EC 5.99.1.3) Drugs in Developmen...

May 2022 68 pages

Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Double Homeobox Protein 4...

May 2022 41 pages

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Dr...

May 2022 64 pages

Drug-Induced Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Drug-Induced Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Drug-Induced Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 55 pages